Penn grads develop The Community Grocer to provide hot food for those using SNAP benefits
Penn graduates Alex Imbot ‘20 and Eli Moraru ‘21 were featured in the Inquirer for their non-profit corner store idea, The Community Grocer, which improves food access for those using SNAP benefits.
Mitchell Named “Young Innovator of Cellular and Molecular Bioengineering”
Mike Mitchell, PhD, J. Peter and Geri Skirkanich Assistant Professor of Innovation in Bioengineering (BE), was named a "Young Innovator of Cellular and Molecular Bioengineering."
New research from the Mitchell Lab offers a safer path for CAR T cell immunotherapy
The new method involves attaching a sugar molecule onto the surface of CAR T cells using metabolic labeling, a modification that enables the CAR T cells to attack cancer cells without any hindrance.
Carl June to receive the 2024 Breakthrough Prize in Life Sciences
June was awarded for the development of chimeric antigen receptor (CAR) T cell immunotherapy.
Penn is the one of the world’s best universities for VC-seeking entrepreneurs, per PitchBook data
PitchBook released its 2023 list of the best universities for founders, and Penn ranked fourth among undergraduate schools with 1,083 founders, 993 companies and $34 billion raised.
Bruce Levine Speaks on the Progress of CAR T at the 2023 CAR-TCR Summit
In this recorded event, which took place on the six-year anniversary of the first approved CAR-T Levine, discusses emerging technology trends that might improve CAR-T therapies.
Mitchell Lab develops a microchip designed to transform the production of mRNA therapeutics and vaccines
“This technology has the potential to become a cornerstone in the field of nanomedicine, beyond RNA-based therapies,” Mitchell said in the Penn Today article.
Press Highlights of FY23
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
Commercialization Speaker Series Engages Penn Faculty, Researchers, and Students
The the Penn Center for Innovation, along with Penn Engineering and Penn Medicine, presented speaker sessions with experts in the field.
Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).